Histone demethylase LSD2 acts as an E3 ubiquitin ligase and inhibits cancer cell growth through promoting proteasomal degradation of OGT

Molecular Cell
Yi YangYanhui Xu

Abstract

Histone demethylases play important roles in various biological processes in a manner dependent on their demethylase activities. However, little is known about their demethylase-independent activities. Here, we report that LSD2, a well-known histone H3K4me1/me2 demethylase, possesses an unexpected E3 ubiquitin ligase activity. LSD2 directly ubiquitylates and promotes proteasome-dependent degradation of O-GlcNAc transferase (OGT), and inhibits A549 lung cancer cell growth in a manner dependent on its E3 ligase activity, but not demethylase activity. The depletion of LSD2 stabilizes OGT and promotes colony formation of 293T cells. LSD2 regulates distinct groups of target genes through histone demethylase and E3 ligase activities, respectively. Such regulation suggests a mechanism through which LSD2 suppresses tumorigenesis by promoting the degradation of OGT and other substrates yet to be discovered. Our study reveals an antigrowth function of LSD2 dependent on its E3 ligase activity and establishes a connection between histone demethylase and ubiquitin-dependent pathway.

References

Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Apr 8, 2004·Neoplasia : an International Journal for Oncology Research·Daniel R RhodesArul M Chinnaiyan
Nov 2, 2005·Nature Reviews. Molecular Cell Biology·Cyrus Martin, Yi Zhang
Sep 21, 2006·Nature Reviews. Genetics·Robert J KloseYi Zhang
May 30, 2009·Science·Maria Cristina GambettaJürg Müller
Aug 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Donald A R SinclairBarry M Honda
Jan 12, 2010·Developmental Cell·Futoshi SuizuMasayuki Noguchi
Apr 9, 2010·Annual Review of Biochemistry·Nima Mosammaparast, Yang Shi
May 22, 2010·Seminars in Cell & Developmental Biology·Dona C LoveJohn A Hanover
Jan 25, 2011·Biochimica Et Biophysica Acta·Wenyi MiWengong Yu
Apr 27, 2011·Cell Cycle·Thomas P Lynch, Mauricio J Reginato
May 14, 2011·Clinical and Experimental Medicine·Anna KrześlakMagdalena Bryś
May 25, 2011·Proceedings of the National Academy of Sciences of the United States of America·Samuel A MyersAlma L Burlingame
Aug 3, 2011·Journal of Cell Science·Chithra N KeembiyehettyJohn A Hanover
Apr 24, 2012·Nature Reviews. Molecular Cell Biology·John A HanoverDona C Love
Nov 14, 2012·Current Opinion in Chemical Biology·David J Vocadlo
May 7, 2013·Annual Review of Nutrition·Michelle R Bond, John A Hanover
Aug 22, 2013·Frontiers in Endocrinology·Yann FardiniTarik Issad
Nov 13, 2013·The Journal of Cell Biology·Nima MosammaparastYang Shi
Mar 7, 2014·Clinical Proteomics·Junfeng Ma, Gerald W Hart

❮ Previous
Next ❯

Citations

Feb 16, 2016·Biochemical and Biophysical Research Communications·Kuan JiangLianwen Zhang
Jun 4, 2016·Molecular Cell·Jean-Pierre Etchegaray, Raul Mostoslavsky
Jun 28, 2016·Journal of Molecular Biology·Christina M FerrerMauricio J Reginato
Jul 29, 2016·Cellular and Molecular Life Sciences : CMLS·Jun TieDaiming Fan
Mar 30, 2018·Journal of Bioenergetics and Biomembranes·John A HanoverMichelle R Bond
Apr 15, 2017·Biochemical Society Transactions·Maïté LeturcqAnne-Sophie Vercoutter-Edouart
Jan 27, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ryuta TakaseMitsuyoshi Nakao
Nov 14, 2015·EMBO Reports·Emilia DimitrovaRobert J Klose
Sep 20, 2017·The Cancer Journal·Michael T McCabeRyan G Kruger
Nov 8, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·James BiwiTony Lefebvre
Apr 30, 2017·Experimental & Molecular Medicine·Kwangbeom HyunJaehoon Kim
Dec 6, 2019·Journal of Hematology & Oncology·Yuan FangBin Yu
May 13, 2020·Epigenomics·Mouhamed IdrissouDominique Bernard-Gallon
Oct 1, 2020·Cell Death & Disease·Hyeon Gyu SeoJin Won Cho
Nov 1, 2020·International Journal of Cancer. Journal International Du Cancer·Jayden SterlingLenka Munoz
Jan 20, 2021·Cell Death and Differentiation·Louis MasclefEl Bachir Affar
Jan 9, 2021·Chemical Reviews·Junfeng MaGerald W Hart
Jun 24, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Sarder ArifuzzamanRabeya Khatun
Mar 27, 2021·Biochemical Society Transactions·Yi Zhu, Gerald W Hart

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.